Pending acquisition: ANI is acquiring Egetis Therapeutics for SEK 11.25 per share in cash. Acceptance period expected November 20 to December 18, 2026.
What they do
The Company's mission is “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing therapeutics through its Rare Disease, Generics, and Brands businesses. On September 16, 2024, the Company acquired Alimera Sciences, Inc. ("Alimera").
Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.
Share structure
Common
23.0M
Pre-funded warrants
0.0M
Options
0.3M
RSUs
1.8M
Warrants
0.0M
Converts
4.3M
Conv preferred
0.0M
ESPP reserve
0.5M
FDSO
29.9M
Cap table as of 2026-06-30.
ANI announced a recommended public cash offer for Egetis Therapeutics on November 5, 2026: SEK 11.25 per Egetis share in cash, about SEK 5.6 billion (about $560M) in total including Egetis incentive programs, plus cash for Egetis's convertible loan and warrants. No ANI shares are issued; the offer is funded with cash on hand and new debt financing from JPMorgan Chase Bank, and it carries no financing condition. Egetis's board unanimously recommends the offer and holders of about 42% of Egetis shares have given irrevocable undertakings to accept. Completion needs acceptances above 90% of Egetis shares on a fully diluted basis and regulatory clearances. The acceptance period is expected to run from about November 20 to about December 18, 2026, with settlement expected around December 29, 2026. The share counts on this page do not change in this deal. ANI's cash and debt on this page are pre-offer standalone figures and will be replaced at settlement, when the cash portion is paid out and the new debt is drawn.
Price history
Loading ANIP daily closes…
Loading price history…
Next catalyst
ILUVIEN · Est. Nov 15, 2026 · quarter midpoint · guided Now
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Licensed from EyePoint (via Alimera collaboration agreement; $75M upfront); Alimera patent rights limited to diseases of the human eye in Europe/Middle East/Africa and certain other territories
Indications
Diabetic macular edema (DME)(Approved)
Chronic non-infectious uveitis affecting the posterior segment (NIU-PS)(Approved)
Status note Approved product; FDA approved an expanded label to include chronic NIU-PS in addition to DME.
Novel pitolisant formulation
Stage not disclosed · Active
Partnerships Co-exclusive license with Harmony/Novitium to develop the formulation; company earns low-single digit royalties on net sales of pitolisant-based products
Indications
Broad central nervous system indications (outside sleep/wake)(Stage not disclosed)
Status note Early-stage development intent only; filing states no clinical stage. Company is primarily a commercial generics/branded pharma; the 10-Q carries no clinical-stage pipeline beyond this candidate.
Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
Fund
Shares
Q/Q change
% of portfolio
Filing
Tang Capital Partners
707,500
no change
2.66%
2026-08-14
Ikarian Capital
272,085
+125,000
3.69%
2026-08-14
Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 718 stocks.